Serum uric acid: Novel prognostic factor in primary systemic amyloidosis

Shaji K Kumar, Angela Dispenzieri, Martha Lacy, Suzanne R. Hayman, Nelson Leung, Steve R. Zeldenrust, Francis K. Buadi, Robert A. Kyle, S Vincent Rajkumar, Morie Gertz

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

OBJECTIVE: To determine the prognostic value of serum uric acid (UA) in patients with primary systemic (light chain) amyloidosis (AL). PATIENTS AND METHODS: A cohort of 1977 patients with newly diagnosed AL seen at our institution between April 1, 1960, and August 1, 2006, and 293 patients with AL who underwent peripheral blood stem cell transplant between March 1, 1996, and October 1, 2006, were studied retrospectively to examine the value of serum UA. The prognostic value of several variables was examined using Cox proportional hazards models, and the survival time was estimated using Kaplan-Meier analysis; curves were compared using the log-rank test. RESULTS: Patients with UA levels greater than 8 mg/dL had a median overall survival of 9 months from diagnosis compared with 20.3 months for the remaining patients (P<.001). The prognostic value of UA was independent of the known cardiac prognostic markers cardiac troponin T (cTnT) and N-terminal propeptide of brain-type natriuretic peptide (NTProBNP). Addition of UA to these factors allows us to classify patients into 4 groups with significantly different outcomes. Patients with none, 1, 2, or 3 of these risk factors (UA, >8 mg/dL; cTnT, >0.035 ng/mL; and NTProBNP, >332 pg/mL) had a median overall survival of 36.6, 29.2, 11.1, and 3.6 months, respectively ( P<.001). Similarly, UA levels helped predict overall survival in patients undergoing peripheral blood stem cell transplant for AL and added to the value of cTnT and NTProBNP. CONCLUSION: The data confirm the prognostic utility of cTnT and NTProBNP in a large group of patients and highlight the value of serum UA in allowing better forecasting of probable outcomes for patients with AL.

Original languageEnglish (US)
Pages (from-to)297-303
Number of pages7
JournalMayo Clinic Proceedings
Volume83
Issue number3
DOIs
StatePublished - 2008

Fingerprint

Uric Acid
Amyloidosis
Serum
Survival
Transplants
Primary amyloidosis
Kaplan-Meier Estimate
Proportional Hazards Models
Light

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Serum uric acid : Novel prognostic factor in primary systemic amyloidosis. / Kumar, Shaji K; Dispenzieri, Angela; Lacy, Martha; Hayman, Suzanne R.; Leung, Nelson; Zeldenrust, Steve R.; Buadi, Francis K.; Kyle, Robert A.; Rajkumar, S Vincent; Gertz, Morie.

In: Mayo Clinic Proceedings, Vol. 83, No. 3, 2008, p. 297-303.

Research output: Contribution to journalArticle

Kumar, Shaji K ; Dispenzieri, Angela ; Lacy, Martha ; Hayman, Suzanne R. ; Leung, Nelson ; Zeldenrust, Steve R. ; Buadi, Francis K. ; Kyle, Robert A. ; Rajkumar, S Vincent ; Gertz, Morie. / Serum uric acid : Novel prognostic factor in primary systemic amyloidosis. In: Mayo Clinic Proceedings. 2008 ; Vol. 83, No. 3. pp. 297-303.
@article{7a06637d4301401f95420ce7ef90d453,
title = "Serum uric acid: Novel prognostic factor in primary systemic amyloidosis",
abstract = "OBJECTIVE: To determine the prognostic value of serum uric acid (UA) in patients with primary systemic (light chain) amyloidosis (AL). PATIENTS AND METHODS: A cohort of 1977 patients with newly diagnosed AL seen at our institution between April 1, 1960, and August 1, 2006, and 293 patients with AL who underwent peripheral blood stem cell transplant between March 1, 1996, and October 1, 2006, were studied retrospectively to examine the value of serum UA. The prognostic value of several variables was examined using Cox proportional hazards models, and the survival time was estimated using Kaplan-Meier analysis; curves were compared using the log-rank test. RESULTS: Patients with UA levels greater than 8 mg/dL had a median overall survival of 9 months from diagnosis compared with 20.3 months for the remaining patients (P<.001). The prognostic value of UA was independent of the known cardiac prognostic markers cardiac troponin T (cTnT) and N-terminal propeptide of brain-type natriuretic peptide (NTProBNP). Addition of UA to these factors allows us to classify patients into 4 groups with significantly different outcomes. Patients with none, 1, 2, or 3 of these risk factors (UA, >8 mg/dL; cTnT, >0.035 ng/mL; and NTProBNP, >332 pg/mL) had a median overall survival of 36.6, 29.2, 11.1, and 3.6 months, respectively ( P<.001). Similarly, UA levels helped predict overall survival in patients undergoing peripheral blood stem cell transplant for AL and added to the value of cTnT and NTProBNP. CONCLUSION: The data confirm the prognostic utility of cTnT and NTProBNP in a large group of patients and highlight the value of serum UA in allowing better forecasting of probable outcomes for patients with AL.",
author = "Kumar, {Shaji K} and Angela Dispenzieri and Martha Lacy and Hayman, {Suzanne R.} and Nelson Leung and Zeldenrust, {Steve R.} and Buadi, {Francis K.} and Kyle, {Robert A.} and Rajkumar, {S Vincent} and Morie Gertz",
year = "2008",
doi = "10.4065/83.3.297",
language = "English (US)",
volume = "83",
pages = "297--303",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "3",

}

TY - JOUR

T1 - Serum uric acid

T2 - Novel prognostic factor in primary systemic amyloidosis

AU - Kumar, Shaji K

AU - Dispenzieri, Angela

AU - Lacy, Martha

AU - Hayman, Suzanne R.

AU - Leung, Nelson

AU - Zeldenrust, Steve R.

AU - Buadi, Francis K.

AU - Kyle, Robert A.

AU - Rajkumar, S Vincent

AU - Gertz, Morie

PY - 2008

Y1 - 2008

N2 - OBJECTIVE: To determine the prognostic value of serum uric acid (UA) in patients with primary systemic (light chain) amyloidosis (AL). PATIENTS AND METHODS: A cohort of 1977 patients with newly diagnosed AL seen at our institution between April 1, 1960, and August 1, 2006, and 293 patients with AL who underwent peripheral blood stem cell transplant between March 1, 1996, and October 1, 2006, were studied retrospectively to examine the value of serum UA. The prognostic value of several variables was examined using Cox proportional hazards models, and the survival time was estimated using Kaplan-Meier analysis; curves were compared using the log-rank test. RESULTS: Patients with UA levels greater than 8 mg/dL had a median overall survival of 9 months from diagnosis compared with 20.3 months for the remaining patients (P<.001). The prognostic value of UA was independent of the known cardiac prognostic markers cardiac troponin T (cTnT) and N-terminal propeptide of brain-type natriuretic peptide (NTProBNP). Addition of UA to these factors allows us to classify patients into 4 groups with significantly different outcomes. Patients with none, 1, 2, or 3 of these risk factors (UA, >8 mg/dL; cTnT, >0.035 ng/mL; and NTProBNP, >332 pg/mL) had a median overall survival of 36.6, 29.2, 11.1, and 3.6 months, respectively ( P<.001). Similarly, UA levels helped predict overall survival in patients undergoing peripheral blood stem cell transplant for AL and added to the value of cTnT and NTProBNP. CONCLUSION: The data confirm the prognostic utility of cTnT and NTProBNP in a large group of patients and highlight the value of serum UA in allowing better forecasting of probable outcomes for patients with AL.

AB - OBJECTIVE: To determine the prognostic value of serum uric acid (UA) in patients with primary systemic (light chain) amyloidosis (AL). PATIENTS AND METHODS: A cohort of 1977 patients with newly diagnosed AL seen at our institution between April 1, 1960, and August 1, 2006, and 293 patients with AL who underwent peripheral blood stem cell transplant between March 1, 1996, and October 1, 2006, were studied retrospectively to examine the value of serum UA. The prognostic value of several variables was examined using Cox proportional hazards models, and the survival time was estimated using Kaplan-Meier analysis; curves were compared using the log-rank test. RESULTS: Patients with UA levels greater than 8 mg/dL had a median overall survival of 9 months from diagnosis compared with 20.3 months for the remaining patients (P<.001). The prognostic value of UA was independent of the known cardiac prognostic markers cardiac troponin T (cTnT) and N-terminal propeptide of brain-type natriuretic peptide (NTProBNP). Addition of UA to these factors allows us to classify patients into 4 groups with significantly different outcomes. Patients with none, 1, 2, or 3 of these risk factors (UA, >8 mg/dL; cTnT, >0.035 ng/mL; and NTProBNP, >332 pg/mL) had a median overall survival of 36.6, 29.2, 11.1, and 3.6 months, respectively ( P<.001). Similarly, UA levels helped predict overall survival in patients undergoing peripheral blood stem cell transplant for AL and added to the value of cTnT and NTProBNP. CONCLUSION: The data confirm the prognostic utility of cTnT and NTProBNP in a large group of patients and highlight the value of serum UA in allowing better forecasting of probable outcomes for patients with AL.

UR - http://www.scopus.com/inward/record.url?scp=41549160287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549160287&partnerID=8YFLogxK

U2 - 10.4065/83.3.297

DO - 10.4065/83.3.297

M3 - Article

C2 - 18315995

AN - SCOPUS:41549160287

VL - 83

SP - 297

EP - 303

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 3

ER -